IP Library Granted Patent US 11,597,740
Granted Patent B2
US 11,597,740 · App. 17/097,488 · Granted Mar 7, 2023

Process for efficient purification of neutral human milk oligosaccharides (HMOs) from microbial fermentation

Inventor: Stefan Jennewein (Bad Honnef, DE)
Assignee: Chr. Hansen HMO GmbH
C07H1/08A23L5/00A23L29/30A23L33/21A23L33/40A61K31/702C07H3/06C12P19/14A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,597,740
App. No.
17/097,488
Granted
Mar 7, 2023
Kind
B2
Abstract

The present application discloses a simple process for the purification of neutral human milk oligosaccharides (HMOs) produced by microbial fermentation. The process uses a combination of cationic ion exchanger treatment, an anionic ion exchanger treatment, and a nanofiltration and/or electrodialysis step, which allows efficient purification of large quantities of neutral HMOs at high purity. Contrary to the purification currently used in fermentative production of neutral HMOs, the presented process allows the provision of HMOs without the need of a chromatographic separation. The so purified HMOs may be obtained in solid form by spray drying, as crystalline material or as sterile filtered concentrate. The provided HMOs are free of proteins and recombinant material originating from the used recombinant microbial strains and thus very well-suited for use in food, medical food and feed (e.g. pet food) applications.

Claims (12)

1. A process for the purification of a neutral human milk oligosaccharide in a batch manner or in a continuous manner from a fermentation broth obtained by microbial fermentation, wherein the neutral human milk oligosaccharide is selected from the group consisting of 3-fucosyllactose, 2′,3-difucosyllactose, lacto-N-triose II, lacto-N-tetraose, lacto-N-neotetraose, lacto-N-fucopentaose I, lacto-N-neofucopentaose, lacto-N-fucopentaose II, lacto-N-fucopentaose III, lacto-N-fucopentaose V, lacto-N-neofucopentaose V, lacto-N-difucohexaose I, lacto-N-difucohexaose II, 6′-galactosyllactose, 3′-galactosyllactose, lacto-N-hexaose and lacto-N-neohexaose, which process comprises

i) separating the microbial biomass from the fermentation broth;

ii) subjecting the solution obtained in step i) to nanofiltration;

iii) subjecting the separated fermentation broth obtained in step ii) to a cation exchanger or to an anion exchanger to obtain a solution;

iv) subjecting the solution obtained in step iii) to the cation or anion exchanger not used in step iii);

v) subjecting the solution obtained from step iv) to nanofiltration or reverse osmosis or vacuum evaporation or electrodialysis to obtain a purified solution of the neutral human milk oligosaccharide;

vi) optionally treating the purified solution obtained after step iv) or step v) with activated carbon; and

vii) spray-drying the purified solution obtained after step v) or vi), wherein the neutral human milk oligosaccharide in the purified solution obtained after step v) or after step vi), has a purity of ≥70% as determined by HPLC.

2. The process of claim 1 , wherein the separating step i) is performed using ultrafiltration using a cross-flow filter.

3. The process of claim 1 , wherein the separated fermentation broth obtained in step i) is diafiltrated before step ii).

4. The process of claim 1 , further comprising adding a β-glucosidase to the fermentation broth prior to step i).

5. The process of claim 1 , wherein step vi) treating the purified solution obtained after step iv) or step v) with activated carbon is performed.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 4, 2025
From: CHR. HANSEN HMO GMBH
To: CHR. HANSEN A/S
Reel/Frame 070396/0299 →
CHANGE OF NAME Recorded Apr 6, 2022
From: JENNEWEIN BIOTECHNOLOGIE GMBH
To: CHR. HANSEN HMO GMBH
Reel/Frame 059617/0804 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 30, 2020
From: JENNEWEIN, STEFAN
To: JENNEWEIN BIOTECHNOLOGIE GMBH
Reel/Frame 054496/0698 →
Priority Claims (1)
EP 14151737 · Jan 20, 2014 · regional
Continuity (3)
Division 16277731 · Feb 15, 2019
Continuation 15112724
Related Publication 20210061836A1 · Mar 4, 2021
Cited By (1)
US 12,735,443